Skip to main content

Advertisement

SpringerLink
Log in

Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy?

  • Colorectal Cancer
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

About 50 % of patients with metastatic colorectal cancer (CRC) will develop metastatic disease with liver as primary metastatic site. The majority of CRC patients has nonresectable disease and receives palliative chemotherapy. Overall survival (OS) from time of progression on last line of chemotherapy in metastatic CRC is about 5 months. CLM have been considered a contraindication for liver transplantation. However, we have previously reported 5-year OS of 60 % after liver transplantation for nonresectable CLM. There were six patients who had progressive disease (PD) on last line of standard chemotherapy at the time of liver transplantation; here we report the outcome for these six patients.

Methods

Patients with nonresectable liver-only CLM received liver transplantation in the SECA study, a subgroup of six patients whose disease had progressed on all standard lines of chemotherapy.

Results

These patients with nonresectable disease and PD on the last line of standard chemotherapy at time of liver transplantation had 8–35 metastatic lesions in the liver with the largest diameter at 2.8–13.0 cm. All patients had a relapse within 2.1–12.4 months after liver transplantation. Some patients received treatment with curative intent at the time of relapse, and median OS after transplantation was 41 months with a Kaplan–Meier calculated 5-year OS of 44 %.

Conclusions

Liver transplantation in nonresectable CLM patients with extensive tumor load and PD on the last line of chemotherapy had extended OS compared with any other treatment option reported in the literature.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283–301.

    PubMed Central  PubMed  Google Scholar 

  2. Masi G, Vasile E, Loupakis F, Cupini S, Fornaro L, Baldi G, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011;103:21–30.

    Article  PubMed  Google Scholar 

  3. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.

    Article  PubMed  Google Scholar 

  4. Glimelius B, Cavalli-Bjorkman N. Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach—present status. Scand J Gastroenterol. 2012;47:296–314.

    Article  CAS  PubMed  Google Scholar 

  5. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–9.

    Article  PubMed  Google Scholar 

  6. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705.

    Article  CAS  PubMed  Google Scholar 

  7. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol. 2012;30:1755–62.

    Article  CAS  PubMed  Google Scholar 

  8. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2311–9.

    Article  CAS  PubMed  Google Scholar 

  9. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44.

    Article  CAS  PubMed  Google Scholar 

  10. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:4706–13.

    Article  CAS  PubMed  Google Scholar 

  11. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12.

    Article  CAS  PubMed  Google Scholar 

  12. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17(Suppl 2):S44–S57.

    Article  PubMed  Google Scholar 

  13. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:e11–e22.

    Article  PubMed Central  PubMed  Google Scholar 

  14. McCashland T, Watt K, Lyden E, Adams L, Charlton M, Smith AD, et al. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl. 2007;13:1246–53.

    Article  PubMed  Google Scholar 

  15. Hagness M, Foss A, Line PD, Scholz T, Jorgensen PF, Fosby B, et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg. 2013;257:800–6.

    Article  PubMed  Google Scholar 

  16. Dueland S, Guren TK, Hagness M, Glimelius B, Line PD, Pfeiffer P, et al. Chemotherapy or liver transplantation for non-resectable liver metastases from colorectal cancer? Ann Surg.

  17. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240:1052–61.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Suzuki C, Blomqvist L, Sundin A, Jacobsson H, Bystrom P, Berglund A, et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol. 2012;23:948–54.

    Article  CAS  PubMed  Google Scholar 

  19. Cercek A, Aguilo A, Gluskin J, Chou JF, Reidy DL, Saltz L, et al. Response rates to hepatic arterial infusion (HAI) pump therapy in patients with metastatic colorectal cancer liver metastases (mCRC LM) after progression on all standard chemotherapies. Poster at ASCO GI, 2014. J Clin Oncol. 2014;32 (suppl 3); abstr 597.

  20. Seidensticker R, Denecke T, Kraus P, Seidensticker M, Mohnike K, Fahlke J, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol. 2012;35:1066–73.

    Article  Google Scholar 

  21. Karapetis CS, Padman SJ, Beeke C, Padbury R, Kitchener M, Kirkwood I, et al. The management of colorectal cancer (CRC) liver metastases with yttrium-90 microspheres (Y90): the south Australian (SA) experience. Poster at ASCO GI, 2014. J Clin Oncol. 2014;32 (suppl 3); abstr 666.

  22. Hagness M, Foss A, Egge TS, Dueland S. Patterns of recurrence after liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg Oncol. 2014;21:1323–9.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Martins PN, Movahedi B, Bozorgzadeh A. Liver transplantation for unresectable colorectal cancer liver metastases: a paradigm change? Ann Surg. 2014.

Download references

Acknowledgment

This work was supported by South-Eastern Norway Regional Health Authority, Oslo University Hospital, and Norwegian Cancer Society.

Disclosure

Svein Dueland, Morten Hagness, Pål-Dag Line, Tormod Kyrre Guren, Kjell Magne Tveit, Aksel Foss has no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Oncology, Oslo University Hospital, Oslo, Norway

    Svein Dueland MD, PhD, Tormod Kyrre Guren MD, PhD & Kjell Magne Tveit MD, PhD

  2. Section for Transplantation Surgery, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway

    Morten Hagness MD, PhD, Pål-Dag Line MD, PhD & Aksel Foss MD, PhD

  3. Institute of Clinical Medicine, University of Oslo, Oslo, Norway

    Morten Hagness MD, PhD, Kjell Magne Tveit MD, PhD & Aksel Foss MD, PhD

  4. K.G.Jebsen Colorectal Cancer Research Center, Oslo University Hospital, Oslo, Norway

    Tormod Kyrre Guren MD, PhD & Kjell Magne Tveit MD, PhD

Authors
  1. Svein Dueland MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Morten Hagness MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pål-Dag Line MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tormod Kyrre Guren MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kjell Magne Tveit MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aksel Foss MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Svein Dueland MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dueland, S., Hagness, M., Line, PD. et al. Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy?. Ann Surg Oncol 22, 2195–2200 (2015). https://doi.org/10.1245/s10434-014-4137-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-4137-0

Keywords

Search

Navigation